Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06623474

Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma

As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people. Therefore, early diagnosis and treatment of primary liver cancer are of great significance. In recent years, the incidence of primary liver cancer, which is caused by hepatic steatosis or metabolic dysfunction-related liver disease, is increasing year by year, and it has become one of the fastest rising causes in some developed countries. More and more studies have also confirmed that the levels of different kinds of lipids and their metabolites are correlated with the development of hepatocellular carcinoma. In this study, the researchers performed qualitative and quantitative analyses of various common lipid metabolites in plasma and liver cancer tissues of hepatic resection patients with hepatocellular carcinoma, collected tumor-related pathological data from the patients, and investigated the correlation between the lipid metabolites and the development of hepatocellular carcinoma, in order to provide a new idea for the early diagnosis and treatment of primary hepatocellular carcinoma, as well as for screening of hepatocellular carcinoma markers.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Nanfang Hospital

Guangzhou, Guangdong, 510515, China

Location status: Recruiting

Location contact

Kai Wang, Doctor

CONTACT

[email protected]

13710574386

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma (diagnostic criteria for hepatocellular carcinoma refer to the guidelines for the diagnosis and treatment of primary hepatocellular carcinoma).
  • Voluntary signing of informed consent

Exclusion criteria

  • In the judgment of the investigator, they are not suitable to participate in this study.
  • Patients with hepatic malignant tumors with invasion of the main portal vein and its first-order branches, the common hepatic duct and its first-order branches, the main hepatic vein and the inferior vena cava, or extrahepatic metastases.
  • Surgery with biliary tract exploration or reconstruction in the presence of biliary obstruction.
  • Surgery combined with splenectomy or splenic artery ligation
  • Preoperative combination of cardiac, pulmonary, renal and other organs with major underlying diseases.

Treatment and study plan

diagnosed by traditional diagnostic markers(such as AFP or CT etc.)

Diagnostic Test

A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).

Other names: diagnosed by lipid metabolites

Primary outcomes

  1. Lipid Metabolite Levels

    Time frame: Pre-operative and 1, 3 and 5 days post-operatively

    Lipids are extracted in the laboratory and sent to specialized laboratories for LC/MS non-targeted lipidomic assays to measure lipid metabolite levels in plasma and tissues.

Study contacts

Contact information is provided by the study sponsor or research team.

Kai Wang, Doctor

CONTACT

[email protected]

13710574386

Sponsors and collaborators

Lead sponsor

Nanfang Hospital, Southern Medical University

Other

Registry information

Important dates

Study start
2024
Primary completion
2032
Study completion
2032
First posted
Oct 2, 2024
Registry last updated
Oct 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.